Nuvalent | Investor Presentation Deck | 42 slides

The slide uses a timeline to show the progression from global strategy execution to product approval, complemented by a list of 2024 milestones.plan_implementation

Open slide detail

The slide uses a split layout with a left-hand sidebar for advisors/board and a right-hand grid for the leadership team.other

Open slide detail

The slide uses a standard pharmaceutical pipeline visualization format.plan_implementation

Open slide detail

The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.frame_problem

Open slide detailBeat · ProblemLoop · Pattern Hunter

The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.present_solution

Open slide detailBeat · SolutionLoop · Pattern Hunter

The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.size_opportunity

Open slide detailBeat · Market SizeLoop · Pattern Hunter

The slide uses a sidebar 'AT A GLANCE' to summarize key product attributes.present_solution

Open slide detail

The slide uses a timeline-based framework to map clinical stages (1L, 2L, 3L+) against standard therapies and unmet needs.present_framework

Open slide detail

The slide uses a matrix-like structure to compare drug generations against clinical outcomes.compare_peers

Open slide detail

The slide uses a split-screen layout to contrast in vitro potency (dot plot) with in vivo efficacy (bar chart).present_solution

Open slide detail

Includes a bar chart for brain penetrance and a dot plot for selectivity index across various mutations.present_solution

Open slide detail

Includes detailed patient enrollment table by dose cohort and trial objectives.show_traction

Open slide detailBeat · TractionLoop · Cost Of Inaction

Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.analyze_data

Open slide detailBeat · TractionLoop · Cost Of Inaction

Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.analyze_data

Open slide detailBeat · TractionLoop · Cost Of Inaction

The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.show_traction

Open slide detailBeat · TractionLoop · Cost Of Inaction

Swimmer plot showing patient-level treatment duration with ongoing status and response markers.show_traction

Open slide detailBeat · Traction

Includes two patient case studies with MRI scans showing baseline vs follow-up results.show_traction

Open slide detailBeat · Traction

Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.show_traction

Open slide detailBeat · Traction

The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.show_traction

Open slide detailBeat · Traction

The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.present_solution

Open slide detailBeat · Traction

Includes a detailed table of patient cohorts and study objectives.plan_implementation

Open slide detailBeat · Traction

The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.present_solution

Open slide detailBeat · Traction

The slide uses a timeline-based framework to contrast treatment options with clinical limitations.frame_problem

Open slide detailBeat · Traction

The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletcompare_peers

Open slide detailBeat · Traction

Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.analyze_data

Open slide detailBeat · Traction

The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.show_traction

Open slide detailBeat · Traction

Data presented in two tables: Patient Characteristics and Treatment History.analyze_data

Open slide detailBeat · Traction

Includes a summary table of ORR and a waterfall plot of tumor regression.show_traction

Open slide detailBeat · Traction

Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.show_traction

Open slide detailBeat · Traction

Data as of 13 Sep 2022. Includes list of specific adverse events by grade.analyze_data

Open slide detailBeat · Traction

RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.show_traction

Open slide detailBeat · Traction

The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.argue_timing

Open slide detail

The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.plan_implementation

Open slide detail

The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.present_solution

Open slide detail

The slide uses three distinct chart types to demonstrate the drug's efficacy and safety profile.present_solution

Open slide detail

The slide uses a timeline framework to connect current clinical program statuses to a future milestone.plan_implementation

Open slide detail

front_matter

Open slide detail